In a report released today, Luca Issi from RBC Capital maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report), with a ...

HC Wainwright reaffirmed their buy rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) in a research ...

Stock analysts at Leerink Partnrs reduced their Q3 2025 earnings per share estimates for Arrowhead Pharmaceuticals in a ...

Arrowhead Pharmaceuticals Inc (ARWR) stock saw a decline, ending the day at $20.76 which represents a decrease of $-0.77 or -3.58% from the prior close of $21.53. The stock opened at $21.23 and ...

Arrowhead Pharmaceuticals Inc (ARWR) stock saw a modest uptick, ending the day at $21.53 which represents a slight increase of $1.82 or 9.23% from the prior close of $19.71. The stock opened at $20.05 ...

On the other hand, Arrowhead Pharmaceuticals has entered into a significant strategic partnership with Sarepta Therapeutics, involving a $500 million upfront payment and a $325 million equity ...

The shares were sold at a price of $21 each, totaling $20,139. Following this transaction, Olukotun holds 35,781 shares ...

Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Milestone Pharmaceuticals (MIST – Research Report) and keeping the ...

A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Short interest is currently not available. Nasdaq provides information of company’s short interest and the average days it takes to cover them. Short interest and days to cover can be used to ...